ROSEN, NATIONAL TRIAL COUNSEL, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - GSK
NEW YORK CITY, NY / ACCESS Newswire / March 16, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds ...
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - GSK
To join the GSK class action, go to https://rosenlegal.com/submit-form/?case_id=34609 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class ...
Zacks Investment Research on MSN2d
Why GSK (GSK) is a Top Momentum Stock for the Long-Term
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...
BioWorld3d
GSK’s $1.15B Idrx buyout leads slow M&A market as deals stay strong
Biopharma deal activity climbed in early 2025, reaching $37.38 billion in the first two months, up from $35.66 billion a year ...
DelveInsight Business Research, LLP: TAGRISSO Sets the Stage for Market Leadership in Oncology with Strong Growth Prospects | DelveInsight
TAGRISSO has become a standard treatment due to its strong efficacy in both first-line and adjuvant settings. The growing prevalence of EGFR mutations, a rise in lung cancer diagnoses, and broader ...
TAGRISSO Sets the Stage for Market Leadership in Oncology with Strong Growth Prospects | DelveInsight
DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase ...